Follow The Filings

CBIO Crescent Biopharma Inc.

Health Care, filed as CRESCENT BIOPHARMA INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 2.2%
  • $24M
  • 1 add

In 2026 Q2 James Silverman added to Crescent Biopharma.

Who owns this now

Largest portfolio weights among holders, up to 2.2% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman Add 2.2%

Who owns CBIO

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 2.2% Add +0.5% 1,319,351 $24M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CBIO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CBIO insider trades
  • $30.6M bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Fairmount Funds Management LLC Director, +3 joint filers
    Buy
    $12.4M 853,450 shares at $14.50 +31% to stake
    Traded Jul 16 Filed Jul 20
    ↗
  2. Fairmount Funds Management LLC Director, +3 joint filers
    Buy
    $18.2M 1,360,000 shares at $13.41 +98% to stake
    Traded Dec 4, 2025 Filed Dec 8, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 16 stock grants and 16 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
424B3 Filing Doc
SCHEDULE 13D/A — Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 2.02 Filing Doc
10-Q/A Filing Doc
424B3 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
424B3 Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue — — $10.84M
Net income -$36.9M -$37.88M -$153.94M
Net margin * — — -1419.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $43.79M $11.09M $236.66M
Total non-current assets * $1.53M $0M $3.64M
Total assets $45.32M $11.09M $240.29M
Total current liabilities $6.84M $5.78M $36.07M
Total non-current liabilities * $0.067M $0M $1.21M
Total equity $38.41M $5.31M $203.01M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$34.88M -$31.1M -$71.53M
Cash from investing -$0.021M $0.02M -$72.92M
Cash from financing $28.82M $0.005M $322.98M
Net change in cash -$6.08M -$31.07M $178.53M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.